The transaction capitalizes on the 2 firm’s mixed geographic strengths, complementary service choices and therapeutic experience to advance industry-leading analysis for improved affected person outcomes.

WILMINGTON, N.C., ALDERLEY PARK, U.Okay, 4 May 2022 – Today, Catalyst Clinical Research, a market-leading supplier of scientific analysis companies, introduced a strategic acquisition of Aptus Clinical to broaden the geographic attain of the 2 corporations, and to boost affected person entry to superior, life-changing therapies. Together, the 2 entities will turn out to be one multi-region scientific analysis group with an accelerated development trajectory in each the U.S. and Europe.

Catalyst’s choices will now embody in depth and expanded scientific consulting companies, because it inherits Aptus’ robust and established relationship with the Experimental Cancer Medicine Centre (ECMC) community to help trial set-up and scientific design enter. Positioned on the forefront of novel most cancers remedy traits, Catalyst’s lively portfolio serves greater than 5,300 most cancers sufferers in want and can develop by practically 600 sufferers concurrent to this acquisition.

“We are thrilled to be working with Aptus Clinical to broaden our attain within the European market, serving purchasers across the globe to assist develop revolutionary new therapies, enhance affected person outcomes and improve our firm’s long-term impression,” mentioned Catalyst Clinical Research CEO, Nick Dyer. “Our complementary service choices and therapeutic space alignment will enhance outcomes for all our purchasers.”

“Catalyst continues to show its capabilities as a frontrunner in oncology scientific improvement and as a most popular strategic acquirer for rising companies,” mentioned Vern Davenport, Partner at NovaQuest Capital Management and Catalyst Board Chairman. “Aptus offers Catalyst with a extremely succesful group of specialists in Europe to speed up its world ambitions, of which we’re extremely supportive.” Catalyst Clinical Research is a portfolio firm of worldwide platform NovaQuest Capital Management, LLC.

Formed in 2014 by three former AstraZeneca scientific improvement specialists, Aptus Clinical has quickly established itself as a specialist CRO providing versatile scientific analysis options in oncology, cell and gene therapies and uncommon illnesses. Together the businesses, working as Catalyst Oncology, will proceed to ship on a portfolio of greater than 100 lively oncology research by way of a community of 500 keenly concerned investigator websites. Additional research outdoors the Oncology therapeutic space can be delivered underneath the Catalyst Flex resolution and working fashions. 

 “We are proud to accomplice with Catalyst to strengthen our shared dedication to delivering innovative science to affected person populations who’re in determined want of recent therapies”, mentioned Aptus Clinical CEO, Dr. Steve McConchie. “We firmly consider Aptus Clinical and Catalyst are higher collectively and look ahead to combining our a long time of expertise in growing and delivering top quality scientific trials to help our mixed organisation to turn out to be a big world supplier of revolutionary scientific analysis options.”

Combined headcount for the unified firm will now exceed 800 workers members. Catalyst may also work to leverage Aptus’ strategic web site relationships integrating them into its personal web site community spanning North America and Europe. The scientific analysis group joined forces with Triangle Biostatistics in 2019, after which with Ce3 in 2020. Although that is Catalyst’s third M&A transaction, it’s its first worldwide union that can speed up and broaden the businesses’ geographic attain tremendously.

About Catalyst Clinical Research:
Catalyst is a scientific improvement group offering extremely customizable scientific analysis options to the worldwide biopharmaceutical {industry} via two established options: Catalyst Flex and Catalyst Oncology. With greater than 700 workers throughout 35 nations, the corporate offers multi-therapeutic world resourcing and practical companies via Catalyst Flex and a full-service oncology CRO providing via Catalyst Oncology. The firm’s versatile service mannequin is constructed from greater than a decade of listening to prospects, devising customer-centric options, and serving to them drive breakthrough scientific improvement research leveraging Catalyst’s knowledgeable groups and revolutionary applied sciences.

Catalyst is a portfolio firm of NovaQuest Capital Management, LLC, a number one healthcare and life sciences funding agency.

About Aptus Clinical:
Aptus Clinical is a scientific contract analysis organisation that specialises within the design, conduct and supply of early part scientific research with a selected focus in oncology, uncommon illnesses, cell and gene therapies. Projects are delivered by a group of extremely skilled drug improvement specialists utilising their in depth community of educational hyperlinks.  Aptus Clinical goals to accomplice with purchasers to assist them remodel their promising science into valued medicines.


Source link

#Catalyst #Clinical #Research #Acquires #Aptus #Clinical #Accelerate #European #Expansion #Broaden #Client #Services #Enhance #Patient #Impact

By Seth A. Dunbar

Seth Dunbar leads clinical research study operations and quality & compliance. He is experienced working with teams to help drug sponsors better leverage eSource data. With 10+ years of experience Seth brings expertise developing eClinical services that integrate data and technology to help companies optimise study execution.

Leave a Reply

Your email address will not be published. Required fields are marked *